MAT2a inhibitors are now in clinical trials for genotypic MTAP−/− cancers, however the MTAP−/− genotype represents fewer than 2% of human colorectal cancers (CRCs), limiting the utility of MAT2a inhibitors in these and other MTAP+/+ cancers. This evidence concerns the gene MAT2A and colorectal cancer.